Artículos de revistas sobre el tema "Open Forum Speakers Bureau"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Open Forum Speakers Bureau".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Emanuel, Robyn M., Zhenya Senyak, Archie McCallister, Mary Cotter, Barbara VanHusen, Claire N. Harrison y Ruben A. Mesa. "The MPN Fatigue Project: Stage 1 Results Of The MPN Forum Internet-Based Survey Among 879 MPN Patients". Blood 122, n.º 21 (15 de noviembre de 2013): 1595. http://dx.doi.org/10.1182/blood.v122.21.1595.1595.
Texto completoBaljevic, Muhamed, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge et al. "Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment". Blood 138, Supplement 1 (5 de noviembre de 2021): 2751. http://dx.doi.org/10.1182/blood-2021-150998.
Texto completoLentzsch, Suzanne, Brea Lipe, Sascha A. Tuchman, Nizar J. Bahlis, William I. Bensinger, Michael Sebag, Heather J. Sutherland et al. "Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)". Blood 138, Supplement 1 (5 de noviembre de 2021): 1651. http://dx.doi.org/10.1182/blood-2021-150232.
Texto completoRoose, Elien, An-Sofie Schelpe, Edwige Tellier, György Sinkovits, Gilles Kaplanski, Maelle Le Besnerais, Ilaria Mancini et al. "Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology". Blood 132, Supplement 1 (29 de noviembre de 2018): 222. http://dx.doi.org/10.1182/blood-2018-99-113762.
Texto completoStein, Eytan M., Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Michael R. Savona, Anthony S. Stein, Richard M. Stone et al. "Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation". Blood 138, Supplement 1 (5 de noviembre de 2021): 1276. http://dx.doi.org/10.1182/blood-2021-146507.
Texto completoPeyvandi, Flora, Bruce A. Schwartz y Sigurd Knaub. "Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency". Blood 132, Supplement 1 (29 de noviembre de 2018): 2501. http://dx.doi.org/10.1182/blood-2018-99-116572.
Texto completoJurczak, Wojciech, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda y Pier Luigi Zinzani. "BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)". Blood 138, Supplement 1 (5 de noviembre de 2021): 3732. http://dx.doi.org/10.1182/blood-2021-145938.
Texto completoCarlo-Stella, Carmelo, Pier Luigi Luigi Zinzani, Anna Sureda, Luís Francisco Araújo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh et al. "A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma". Blood 138, Supplement 1 (5 de noviembre de 2021): 4362. http://dx.doi.org/10.1182/blood-2021-148431.
Texto completoJurczak, Wojciech, Pier Luigi Zinzani, Georg Hess, Gianluca Gaidano, Mariano Provencio, Zsolt Nagy, Tadeusz Robak et al. "A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis". Blood 134, Supplement_1 (13 de noviembre de 2019): 4078. http://dx.doi.org/10.1182/blood-2019-124297.
Texto completoPeyvandi, Flora, Bruce A. Schwartz y Sigurd Knaub. "Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study". Blood 132, Supplement 1 (29 de noviembre de 2018): 2502. http://dx.doi.org/10.1182/blood-2018-99-116440.
Texto completoKornauth, Christoph, Tea Pemovska, Gregory Ian Vladimer, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner et al. "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial". Blood 136, Supplement 1 (5 de noviembre de 2020): 2–4. http://dx.doi.org/10.1182/blood-2020-140831.
Texto completoYoung, Guy, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin et al. "HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors". Blood 130, Suppl_1 (7 de diciembre de 2017): 85. http://dx.doi.org/10.1182/blood.v130.suppl_1.85.85.
Texto completoOldenburg, Johannes, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria y Mark Reding. "Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study". Blood 134, Supplement_1 (13 de noviembre de 2019): 4943. http://dx.doi.org/10.1182/blood-2019-128140.
Texto completoMiesbach, Wolfgang A., Giovanni Di Minno, Elena Santagostino, Dr Klamroth, Inga Bayh, Amaryllis Soto y Cedric Hermans. "Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data". Blood 134, Supplement_1 (13 de noviembre de 2019): 1117. http://dx.doi.org/10.1182/blood-2019-128486.
Texto completoKojima, S., T. Iwamoto, Y. Kobayashi, M. Kato, F. Takizawa, T. Ida, Y. Toda et al. "POS0572 IMMUNOGENICITY AND SAFETY OF ADJUVANTED RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de mayo de 2023): 554.2–555. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1608.
Texto completoPeyvandi, Flora, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian et al. "Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura". Blood 132, Supplement 1 (29 de noviembre de 2018): 373. http://dx.doi.org/10.1182/blood-2018-99-112125.
Texto completoRaje, Noopur, Paul Richardson, Parameswaran N. Hari, Anuj Mahindra, Sarah Kaster, Christine Connolly, Linda Rivera et al. "An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma." Blood 114, n.º 22 (20 de noviembre de 2009): 3856. http://dx.doi.org/10.1182/blood.v114.22.3856.3856.
Texto completoChavez, Julio C., Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon et al. "The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial". Blood 138, Supplement 1 (5 de noviembre de 2021): 45. http://dx.doi.org/10.1182/blood-2021-147425.
Texto completoNoy, Ariela, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher Flowers, Franck Morschhauser, Graham P. Collins et al. "Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study". Blood 128, n.º 22 (2 de diciembre de 2016): 1213. http://dx.doi.org/10.1182/blood.v128.22.1213.1213.
Texto completoKremer Hovinga, Johanna A., Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Javier De La Rubia et al. "Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study". Blood 132, Supplement 1 (29 de noviembre de 2018): 3744. http://dx.doi.org/10.1182/blood-2018-99-112177.
Texto completoSiegel, David S., Gary J. Schiller, Christy J. Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous et al. "Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial". Blood 136, Supplement 1 (5 de noviembre de 2020): 16–17. http://dx.doi.org/10.1182/blood-2020-134189.
Texto completoDreyling, Martin, Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro et al. "Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma". Blood 134, Supplement_1 (13 de noviembre de 2019): 1531. http://dx.doi.org/10.1182/blood-2019-121932.
Texto completoPerkins, Andrew Charles, Kate Burbury, Thomas Lehmann, David M. Ross, Andreas Reiter, Vikas Gupta, Claire Harrison et al. "Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis". Blood 136, Supplement 1 (5 de noviembre de 2020): 52–53. http://dx.doi.org/10.1182/blood-2020-140408.
Texto completoZinzani, Pier Luigi, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A. Follows, Georg Lenz, Won Seog Kim et al. "Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies". Blood 134, Supplement_1 (13 de noviembre de 2019): 4009. http://dx.doi.org/10.1182/blood-2019-131779.
Texto completoDadwal, Sanjeet S., Michael Shuster, Gary Douglas Myers, Keith Boundy, Marshelle Warren, Elizabeth Stoner, Thuy Truong y Joshua A. Hill. "Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial". Blood 138, Supplement 1 (5 de noviembre de 2021): 1760. http://dx.doi.org/10.1182/blood-2021-152553.
Texto completoPaschka, Peter, Hervé Dombret, Xavier Thomas, Christian Recher, Sylvain Chantepie, Pau Montesinos Fernandez, Evelyn Acuña-Cruz et al. "Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls". Blood 136, Supplement 1 (5 de noviembre de 2020): 18–19. http://dx.doi.org/10.1182/blood-2020-136957.
Texto completoKumagai, Takashi, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi et al. "Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial". Blood 138, Supplement 1 (5 de noviembre de 2021): 3601. http://dx.doi.org/10.1182/blood-2021-149483.
Texto completoStilgenbauer, Stephan, Francesc Bosch, Véronique Leblond, Osman Ilhan, Jens Kisro, Béatrice Mahé, Eva Mikuskova et al. "Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy". Blood 134, Supplement_1 (13 de noviembre de 2019): 3035. http://dx.doi.org/10.1182/blood-2019-123419.
Texto completoShapiro, Amy, Giancarlo Castaman, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, Silva Zupancic-Salek y Victor Jimenez-Yuste. "Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial". Blood 134, Supplement_1 (13 de noviembre de 2019): 1139. http://dx.doi.org/10.1182/blood-2019-122809.
Texto completoJurczak, Wojciech, Pier Luigi Luigi Zinzani, David Cunningham, Michel Azoulay, Wenying Huang, Weiming Xu y Vincent Ribrag. "Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)". Blood 138, Supplement 1 (5 de noviembre de 2021): 2430. http://dx.doi.org/10.1182/blood-2021-148015.
Texto completoMato, Anthony R., William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu et al. "BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)". Blood 138, Supplement 1 (5 de noviembre de 2021): 3742. http://dx.doi.org/10.1182/blood-2021-145936.
Texto completoUsmani, Saad Z., Maria-Victoria Mateos, Hareth Nahi, Sebastian Grosicki, Vladimir I. Vorobyev, Ivan Spicka, Vania T. M. Hungria et al. "Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update". Blood 134, Supplement_1 (13 de noviembre de 2019): 1865. http://dx.doi.org/10.1182/blood-2019-122765.
Texto completoMatsumura, Itaru, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko et al. "Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212". Blood 136, Supplement 1 (5 de noviembre de 2020): 40–41. http://dx.doi.org/10.1182/blood-2020-134168.
Texto completoHampton, Kingsley, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, Lotte Jacobsen, Anne T. Neff, Elena Santagostino et al. "First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a". Blood 126, n.º 23 (3 de diciembre de 2015): 2283. http://dx.doi.org/10.1182/blood.v126.23.2283.2283.
Texto completoNeelapu, Sattva S., Mohamed A. Kharfan-Dabaja, Olalekan O. Oluwole, Patel Krish, Ran Reshef, Peter A. Riedell, Parveen Shiraz et al. "A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)". Blood 134, Supplement_1 (13 de noviembre de 2019): 4093. http://dx.doi.org/10.1182/blood-2019-126369.
Texto completoBailey, Neil, Tenzin Tsomo, Jennie Szeto, William I. Bensinger, Daniel Egan, Livia Hegerova, Raya Mawad et al. "Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Blood 136, Supplement 1 (5 de noviembre de 2020): 34. http://dx.doi.org/10.1182/blood-2020-141074.
Texto completoElsawy, Mahmoud, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman et al. "Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)". Blood 138, Supplement 1 (5 de noviembre de 2021): 430. http://dx.doi.org/10.1182/blood-2021-147598.
Texto completoStewart, A. Keith, S. Vincent Rajkumar, Meletios A. Dimopoulos, Tamás Masszi, Ivan Spicka, Albert Oriol, Roman Hájek et al. "Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study". Blood 124, n.º 21 (6 de diciembre de 2014): 79. http://dx.doi.org/10.1182/blood.v124.21.79.79.
Texto completoBussel, James B., Francesco Rodeghiero, Roger M. Lyons, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, Louis Terriou, Roberto Stasi, Paul Chang y Susie Jun. "Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases",. Blood 118, n.º 21 (18 de noviembre de 2011): 3281. http://dx.doi.org/10.1182/blood.v118.21.3281.3281.
Texto completoZinzani, Pier Luigi, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny et al. "Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial". Blood 136, Supplement 1 (5 de noviembre de 2020): 34–35. http://dx.doi.org/10.1182/blood-2020-134851.
Texto completoVannucchi, Alessandro M., Heinz Gisslinger, Claire N. Harrison, Haifa Kathrin Al-Ali, Ester Pungolino, Jean-Jacques Kiladjian, Francoise Boyer-Perrard et al. "EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline". Blood 126, n.º 23 (3 de diciembre de 2015): 2817. http://dx.doi.org/10.1182/blood.v126.23.2817.2817.
Texto completoSantagostino, Elena, Kathelijn Fischer, Christoph Koenigs, Claudia Djambas Khayat, Samantha Lucas, Blanca Salazar, Andres Brainsky, Thomas Chung, Brahm Goldstein y Johnny Mahlangu. "Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)". Blood 134, Supplement_1 (13 de noviembre de 2019): 162. http://dx.doi.org/10.1182/blood-2019-123981.
Texto completoLonial, Sagar, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan et al. "Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma". Blood 138, Supplement 1 (5 de noviembre de 2021): 2742. http://dx.doi.org/10.1182/blood-2021-148385.
Texto completoChiaretti, Sabina, Renato Bassan, Antonella Vitale, Loredana Elia, Alfonso Piciocchi, Cristina Puzzolo, Martina Canichella et al. "Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial". Blood 134, Supplement_1 (13 de noviembre de 2019): 740. http://dx.doi.org/10.1182/blood-2019-128759.
Texto completoDucore, Jonathan M., Shadan Lalezari, Elena Santagostino, Sanjay P. Ahuja, Monika Maas Enriquez, Claudia Tueckmantel y Mark Reding. "Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study". Blood 134, Supplement_1 (13 de noviembre de 2019): 1129. http://dx.doi.org/10.1182/blood-2019-123947.
Texto completoJimenez-Yuste, Victor, Midori Shima, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron y Gallia G. Levy. "Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)". Blood 130, Suppl_1 (7 de diciembre de 2017): 86. http://dx.doi.org/10.1182/blood.v130.suppl_1.86.86.
Texto completoMackensen, Andreas, Linda Hanssens, Matthias Stelljes, Wolfgang A. Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner et al. "A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts". Blood 138, Supplement 1 (5 de noviembre de 2021): 3836. http://dx.doi.org/10.1182/blood-2021-152452.
Texto completoZinzani, Pier Luigi, Vincent Delwail, Shankara Paneesha, Simon Rule, Alejandro Martin Garcia-Sancho, Ana Marin-Niebla, Gilles Salles et al. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)". Blood 136, Supplement 1 (5 de noviembre de 2020): 43–44. http://dx.doi.org/10.1182/blood-2020-134609.
Texto completoÁlvarez Roman, Teresa, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Mónica Martín, María Isabel Rivas Pollmar, Raul Justo Sanz, Sara García Barcenilla et al. "Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein". Blood 134, Supplement_1 (13 de noviembre de 2019): 4929. http://dx.doi.org/10.1182/blood-2019-127878.
Texto completoMehta, Amitkumar, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane et al. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)". Blood 136, Supplement 1 (5 de noviembre de 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-134872.
Texto completo